VX-950 (Telaprevir) | HCV protease inhibitor

Loading... Please wait...

New Products

VAHTS Library Quantification Kit for Illumina NQ101-NQ104

$350.00

Choose Options
Equalbit 1x dsDNA HS Assay Kit EQ121

$95.00

Choose Options
VAHTS RNA Clean Beads N412

$175.00

Choose Options
Ribo-off rRNA Depletion Kit (Plant) N409

$550.00

Choose Options
DNA Polymerase I Klenow Fragment exo- N105

$790.00

Choose Options

Our Newsletter

VX-950 (Telaprevir) | HCV protease inhibitor

Price:

$159.00

Catalog #:

C8995-2s

* Package Size:

2 mg (10 mM solution in DMSO)
2 mg (powder)
10 mg (powder)
50 mg (powder)

Quantity:

Buy in bulk and save

For larger amounts,
please Email us for a quote.

Product Description

VX-950 (Telaprevir) is an orally-available, highly-selective, reversible, peptidomimetic inhibitor of HCV NS3-4A protease with an IC50 of 0.35 uM and IC90 of 0.83 uM in an HCV replicon assay [1, 2] In human fetal hepatocytes with genotype 1a HCV-postive patient serum, VX-950 has an IC50 of 280 uM. [3] VX-950 reduces HCV RNA levels in a time- and dose-dependent manner with IC50s of 0.57, 0.49, 0.21, and 0.14 uM following a 24-, 48-, 72-, and 120-h incubation.

VX-950 forms a covalent, but reversible complex in a slow-on, slow-ff process with a steady-state inhibition constant (Ki) of 7 nM. [3] Excellent efficacy with high liver exposure in an HCV NS3-4A mouse model was observed with VX-950.

Technical information:

Chemical Formula:		C₃₆H₅₃N₇O₆
CAS #:		402957-28-2
Molecular Weight:		679.85
Purity:		>98%
Appearance:		White
Chemical Name:		(1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
Solubility:		Up to 100mM in DMSO
Synonyms:		VX-950, VX-950, Telaprevir, Incivek, Incivo

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

1.	Lin et al., VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob. Agents Chemother. 2006, 50(5), 1813-1822. Pubmed ID: 16641454
2.	Lin et al., Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infectious Disorders: Drug Targets, 2006, 6(1), 3-16. Pubmed ID: 16787300
3.	Perni et al., Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 2006, 50(3), 899-909. Pubmed ID: 16495249

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.